BerGenBio

AGM Information • May 29, 2020

BerGenBio ASA: Notice of Extraordinary general meeting

BerGenBio ASA: Notice of Extraordinary general meeting

Bergen, Norway, 29 May 2020 - Notice is hereby given of an Extraordinary General

Meeting in BerGenBioASA will be held on 19 June 2020 at 15:00 hours (CET) at the

Company's offices in Møllendalsbakken 9, 5009 Bergen.

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is available

at https://www.bergenbio.com/investors/general-

meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

Due to COVID-19 related restrictions and the advice from the Norwegian

government all shareholders are encouraged to exercise their shareholder rights

without physical attendance at the general meeting, either through advance

electronically voting through VPS Investor Services or by using the enclosed

proxy form to provide proxy to the Chairman Sveinung Hole (or the person he

appoints).

Notice of attendance, advance vote or proxy for the Extraordinary General

Meeting can be registered through the company's website or VPS Investor Service.

All registered shareholders will receive a reference number and a pin code

required for registration through the company's website. Reference number and

pin code will be received either by VPS Investor Service or by post depending if

the shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS to save

environment impact.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on

developing transformative drugs targeting AXL as a potential cornerstone of

therapy for aggressive diseases, including immune-evasive, therapy resistant

cancers and infectious diseases. The company's proprietary lead candidate,

bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad

Phase II oncology clinical development programme focused on combination and

single agent therapyin lung cancer and leukaemia. A first-in-class functional

blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing.

In parallel,BerGenBio is developing companion diagnostic tests to identify those

patient populations most likely to benefit from bemcentinib: this is expected

to facilitate more efficient registration trials supporting a precision medicine

-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For

more information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.